McKesson Corporation (MCK)
McKesson raises annual profit forecast on strength in its U.S. pharma segment
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.
Should You Buy, Sell or Hold McKesson Before Q2 Earnings?
MCK's second-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, McKesson (MCK) closed at $508.95, marking a +0.3% move from the previous day.
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Rises As Market Takes a Dip: Key Facts
In the latest trading session, McKesson (MCK) closed at $513.67, marking a +0.86% move from the previous day.
Is Trending Stock McKesson Corporation (MCK) a Buy Now?
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock is giving investors a nice entry point as it reverts to the mean S&P500 returns. The company was the highest-scoring large cap on the most recent Magic Formula screen for October 2024.
McKesson (MCK) Stock Dips While Market Gains: Key Facts
McKesson (MCK) reachead $488.78 at the closing of the latest trading day, reflecting a -1.95% change compared to its last close.
Here's Why McKesson (MCK) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
